Results 181 to 190 of about 269,557 (334)
Erythema Nodosum Leprosum Triggered by Herpes Simplex Infection: A Case Report. [PDF]
Al-Anbagi U +5 more
europepmc +1 more source
Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska +8 more
wiley +1 more source
Eczematous molluscum contagiosum masquerading as herpes simplex in an 8-year-old: A case report. [PDF]
Atique A +5 more
europepmc +1 more source
In this study, we characterize a distinct subpopulation of undifferentiated invariant natural killer T (iNKT) cells in the peripheral blood of healthy adults, which are characterized by CD38 expression in a resting state. This CD38+ subset closely resembles iNKT cells from cord blood and thymus, exhibiting a unique cytokine profile and alterations in ...
Christopher Menne +13 more
wiley +1 more source
Herpes simplex virus associated rhomboencephalitis mimicking demyelination: a case report. [PDF]
Lodha N +8 more
europepmc +1 more source
Tissue Resident Memory Cells: Friend or Foe?
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude +2 more
wiley +1 more source
An Evidence Based Review on Oriental Medicine for the Treatment of Herpes Simplex Infections and Their Availability in Iran [PDF]
Hoda Azizi +10 more
openalex +1 more source
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin +24 more
wiley +1 more source

